Cambridge, Mass. (May 7, 2015) – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced it has entered into an exclusive worldwide licensing agreement with The University of Texas Health Science Center at San Antonio. The license grants Astrocyte Pharmaceuticals the exclusive use of patent rights owned by the UT Health Science Center and …
Cambridge, Mass., May 1, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Theodore E. Liston, Ph.D. has joined the company as Vice President of Pharmacokinetics and Pharmacodynamics (PK/PD). Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion …
The 5th Annual Traumatic Brain Injury (TBI) Conference is being held on April 15 and 16, 2015 in Washington DC. The conference will feature the latest research findings from many leading TBI researchers in the areas of neurotrauma, PTSD and concussion and presents an excellent opportunity to hear the latest updates in TBI. Dr. James …
Astrocyte’s Dr. James Lechleiter to Present at 2015 TBI Conference Read More »
Cambridge, Mass., December 1, 2014 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Ives, Ph.D. has joined the company’s Board of Directors. Dr. Ives brings extensive scientific expertise in neuroscience, medicinal chemistry, drug metabolism and pharmacokinetics as well as broad business expertise in biotech partnerships, R&D operations, clinical development, …
